12.2.2021 13:57:07 CET | ViroGates |
Company Announcement
Company Announcement – No. 4 – 2021
BIRKERØD, DENMARK – ViroGates A/S, a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, announces new clinical routine customers in Greece.
ViroGates has received the first order from a new clinical routine customer located in the Attica region close to Athens. The customer is a public hospital offering a range of services, including acute care. The hospital has 550 beds, and the uptake population of the hospital is approximately 550,000 people. The hospital will immediately implement suPARnostic® TurbiLatex on its Roche cobas 501 system for use in the emergency department. The hospital became aware of the possibilities with suPARnostic® through its participation in the recently announced SAVE-MORE study.
In addition to this customer, ViroGates has started receiving TurbiLatex orders from two other hospitals in Greece. ViroGates’ local sales agent now equally considers these two hospitals as clinical routine customers due to the orders’ recent recurring nature.
ViroGates serves all customers in Greece through a local agent from its headquarter in Denmark. Due to the customers’ internal policies, ViroGates cannot disclose the names of the hospitals.
Jakob Knudsen, Chief Executive Officer of ViroGates, said: ”We are happy to announce hospitals in Greece that are now using suPARnostic® TurbiLatex as part of their clinical routine practice. We have worked with clinical opinion leaders and direct marketing in the Greek market for a while, which has now materialized in clinical use in Greece. One of the new clinical routine customers became familiar with suPARnostic® through the recently announced SAVE-MORE clinical study. The publicity associated with this announcement has spurred a general interest in how our products can help hospitals deal with crowding in emergency departments and point to patients that need additional pharmacological care.
The announcement can be found at https://www.virogates.com/investor/announcements
For further information, please contact:
ViroGates A/S:
CEO, Jakob Knudsen
Tel. (+45) 2226 1355, email: jk@virogates.com
Certified Advisor:
Västra Hamnen Corporate Finance
Per Lönn
Tel. (+46) 40 200 250, email: per.lonn@vhcorp.se
About ViroGates
ViroGates A/S is an international medical technology company developing and marketing blood test products under the suPARnostic® brand for better triaging in hospitals to improve patient care, reduce healthcare costs and empower clinical staff.
The company was founded in 2000 based on the discovery that suPAR was predictive of outcome in HIV-infections and subsequently in many other disease areas. Headquartered in Denmark, ViroGates’ sales force covers the Nordics, Spain, and France, while distributors serve other markets.
ViroGates’ shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit www.virogates.com.
About suPAR and suPARnostic®
suPAR is the biomarker detected by ViroGates’ suPARnostic® products and is a protein in plasma, measurable in every human being. suPAR is considered a general risk status biomarker indicating disease presence, disease severity and progression, organ damage and mortality risk across disease areas such as cardiovascular diseases, kidney diseases, type 2 diabetes, cancer, etc. Strong scientific evidence from more than 600 clinical trials and studies show that the higher the level of suPAR, the worse the prognosis for the patient.
The suPARnostic® products can be used to support healthcare professionals in making clinical decisions on hospitalization or discharge of acute care patients. The increasing demands on health systems globally and tightening healthcare budgets necessitate efficiency improvements and innovative solutions in hospitals. The use of suPAR in clinical routine in emergency departments can improve patient care and reduce healthcare costs by increasing the number of discharges by 34% and reducing the average hospital length-of-stay by 6% without affecting mortality. suPARnostic® TurbiLatex is currently available on Roche Diagnostics’ cobas instruments, Siemens ADVIA XPT instruments and the Abbott Labs Architect instruments. ViroGates works with partners to develop solutions for other platforms.
Disclaimer
Prospects about the future reflect ViroGates’ current expectations for future events and results. The statements are by nature inherent in risks, uncertainties and other matters that are difficult to predict or out of control. The actual results may therefore differ from the expectations expressed.
Contacts
Jakob Knudsen, CEO, +45 2226 1355, jk@virogates.com
Attachments
20210212-ViroGates Company announcement 4.pdf
